PLX Stock Discussion

Protalix BioTherapeutics, Inc. Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company's product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications; and an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant enzyme produced within carrot cells. Its product pipeline also comprises PRX-106 or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor and an antibody portion, which is being developed as a treatment of certain immune diseases, such as rheumatoid arthritis, Chrohn's disease, placque psoriasis, and other autoimmune disorders; and two additional undisclosed therapeutic proteins that are being evaluated in animal studies. It has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. The company was founded in 1993 and is based in Carmiel, Israel.

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Psoriasis Rheumatoid Arthritis Autoimmune Disorders Immune Disorders Pharmaceutical Industries Biodefense Choline Fusion Protein Enzyme Replacement Therapy Fabry Disease Teva Pharmaceutical Industries Cholinesterase Gaucher Disease Recombinant Dna Treatment Of Fabry Disease
S

SociableGnat503 over 1 year ago

This looks like it's on the upswing in response to the favorable earnings report and good analyst coverage.  Is the upward action on charts reliable?

0 Reply
T

TraderMike over 1 year ago

I guess it depends on what you mean by "reliable".  Nothing is 100%... that's what stop losses are for.  There are some good, nearby spots in which to place a stop, like the 20 or 200 DMAs

0 Reply
S

SociableGnat503 over 1 year ago

Based on the analysis that says the following :  PLX closed up 1.59 percent on Friday, August 11, 2023, on 51 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought. 

So just trying to make sense of when to when to actually buy or stop buying given this.  

0 Reply
S

SociableGnat503 about 1 year ago

Does the chart analysis taking into account the amount of volume when assigning grades to the ticker? I've noted a drop in exchanged shares over the past few days and not sure if this lack of liquidity poses a risk to the share price.

1 Reply
T

TraderMike about 1 year ago

No, volume is not a factor in the letter grades.  It's primarily where the stock is in relation to major moving averages and its position in its 52 week range

0 Reply